RxDoctor Payments Data

Rachel Wise

Psychiatric/Mental Health · Chattanooga, TNNPI 1205524857

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 26 payments — averaging $45.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$374
  • Vanda Pharmaceuticals Inc.$180
  • Axsome Therapeutics, Inc.$167
  • E.r. Squibb & Sons, L.L.C.$133
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$124
  • Otsuka America Pharmaceutical, Inc.$60
  • plus $149 from 5 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 60th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,332
Medicare patients
40
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine14$89,558
AustedoDeutetrabenazine13$78,209
RexultiBrexpiprazole43$62,879
VraylarCariprazine Hcl37$52,308
CaplytaLumateperone Tosylate13$22,009
TrintellixVortioxetine Hydrobromide25$12,402
Aripiprazole64$6,887
Lurasidone Hcl40$6,170
Oxcarbazepine30$2,163
Hydroxyzine Hcl75$1,811
Atomoxetine Hcl12$1,433
Buspirone Hcl55$1,101
Fluoxetine Hcl54$951
Doxepin Hcl11$900
Quetiapine Fumarate41$717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$374$167,76727 claims
Otsuka America Pharmaceutical, Inc.Rexulti$60$62,87943 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$124$22,00913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →